DUBLIN – Shares in Thrombogenics NV rose 16 percent Monday on news that the Alcon unit of Novartis AG was handing back ex-U.S. rights to Jetrea (ocriplasmin), while also providing a cash payment of €53.7 million (US$64.2 million) and an equity investment of €10 million to the Leuven, Belgium-based biotech.